ONO-2921
ONO-2921 is an orally active and selective N-type calcium channel blocker. ONO-2921 functionally blocks N-type calcium channels. ONO-2921 reduces paw withdrawal responses during persistent nociception and hyperalgesia to heat in neuropathic pain models. ONO-2921 can be used for research on neuropathic pain and nociceptive pain.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 253306-39-7
- Formel: C31H48N4O4S2
- Molecular Weight:604.87
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Calcium Channel Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| IMR-32 | IC50 |
0.33 μM
Compound: 9
|
In vitro inhibition of N-type calcium channel influx in IMR-32 human neuroblastoma cells
In vitro inhibition of N-type calcium channel influx in IMR-32 human neuroblastoma cells
|
[PMID: 12161113] |
ONO-2921 (compound 9) inhibits N-type calcium channels in IMR-32 human neuroblastoma cells with an IC50 of 0.33 μM, and exhibits 15-fold selectivity over L-type calcium channels in AtT-20 mouse pituitary tumor-derived cells[1].
ONO-2921 (3 μM) inhibits 76% of N-type calcium channel currents in IMR-32 human neuroblastoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
ONO-2921 (30 mg/kg; p.o.; single administration) produces significant analgesic effects in the rat CCI neuropathic pain model[1].
ONO-2921 (100 mg/kg; p.o.; single administration) causes no significant cardiovascular or neurological side effects in healthy brown rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rats treated formalin[1]
-
Dosage:10 mg/kg
-
Administration:p.o.; single dose
-
Result:Significantly inhibited paw flinching during the persistent nociceptive phase .
-
Animal Model:Rats with chronic constriction injury (CCI)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; single dose
-
Result:Exhibited significant antinociceptive effects on thermal hyperalgesia induced by sciatic nerve CCI.
Chemical Information
-
CAS. Nr. 253306-39-7
-
Molecular Weight 604.87
-
Formel C31H48N4O4S2
-
SMILES
O=C(NC1CCN(CC1)CC2=CC=CC=C2)[C@H](CSCC3CCCCC3)NC([C@H]4N(CSC4)C(OC(C)(C)C)=O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
ONO-2921 Related Classifications
HY-182351 Related Classifications
Powered by Bioz
- ONO-2921
- 253306-39-7
- ONO2921
- ONO 2921
- Calcium Channel
- rats
- L-type calcium channels
- rat CCI neuropathic pain model
- thermal hyperalgesia
- neuropathic pain
- IMR-32 human neuroblastoma cells
- nociceptive pain
- AtT-20 mouse pituitary tumor-derived cells
- N-type calcium channels
- rat formalin-induced pain model
- Inhibitor
- inhibitor
- inhibit